HIV-1 multi-antigen specific T-cell therapy (Catherine Bollard Children's Research Institute)

N/A

Report date: 2022/12/15 19:41:27

Base Information

Drug NameHIV-1 multi-antigen specific T-cell therapy (Catherine Bollard Children's Research Institute)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCatherine Bollard Children'S Research Institute
China Registration ClassN/A

Develop Information

Active CompaniesCatherine Bollard Children'S Research Institute
Inactive CompaniesN/A
Active IndicationsHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A